NO. 016 · BASIC · Lv. 60 · HP 95
ADAMAX
ARA-290 peptide analog · tissue-protective research compound
ALIASES
Adamax, ARA-290-related peptide, Cibinetide-class
CLASS
EPO-derived non-erythropoietic peptide analog (research-grade)
HALF-LIFE
Short plasma (minutes)
ROUTES
Subcutaneous (research)
MECHANISM OF ACTION
EPO-derived peptide analog related to ARA-290 / cibinetide. Acts through the innate-repair-receptor (IRR) heterocomplex (EPOR + βcR). Studied for tissue-protective signaling without erythropoietic activity.
EVIDENCE GRADES
ARA-290 and related EPO analogs are well-documented activators of the innate-repair-receptor heterocomplex (EPOR + βcR).
ARA-290 shows neuroprotective effects in rodent models of diabetic neuropathy and ischemic injury.
ARA-290 has small-cohort clinical data in sarcoidosis-related small-fiber neuropathy. Limited Western RCT data for Adamax specifically.
MECHANISM CATEGORIES
RESEARCH CONDITIONS
SAFETY
Side effects
- Limited human safety data
- Importantly: no erythropoietic activity at standard research doses (the engineering goal)
Drug interactions
- Unstudied · theoretical interactions with EPO or anti-inflammatory medications
Contraindications
- Pregnancy/lactation (unstudied)
- Active malignancy (theoretical EPO-pathway concern)
REGULATORY STATUS
FDA · Not FDA-approved. Research chemical.
WADA · EPO-class status under S2 may apply depending on specific analog. Buyers should verify with current WADA list.
STORAGE
Lyophilized · 4 °C, 12+ months
Reconstituted · 2–8 °C, 28 days
PEER-REVIEWED EVIDENCE
- Brines M, Patel NS, Villa P, et al.. ARA-290, a non-erythropoietic EPO analog, modulates inflammation and tissue protection. Mol Med 2014. link →
FAQ · 6 QUESTIONS
▶ What is Adamax?
Adamax is a research-grade EPO-derived peptide analog related to ARA-290 (cibinetide). Engineered to activate the innate-repair-receptor (IRR) heterocomplex — EPOR + βcR — without stimulating red-blood-cell production.
▶ Is Adamax FDA-approved?
No. Adamax is a research chemical. Cibinetide (the closely related ARA-290) has been investigated in small clinical trials for sarcoidosis-related small-fiber neuropathy; no FDA approval as of 2026.
▶ How does Adamax differ from EPO?
Native EPO activates both the homodimeric EPOR (driving erythropoiesis) and the IRR heterocomplex (driving tissue protection). Adamax-class peptides are engineered to selectively activate only the IRR, preserving the tissue-protective biology without the red-blood-cell-stimulating side effect.
▶ What is the innate repair receptor (IRR)?
The IRR is a heterocomplex of the EPO receptor (EPOR) and the common beta-chain receptor (βcR / CD131). It mediates the tissue-protective, anti-inflammatory, and neuroprotective biology of EPO without driving red-blood-cell production.
▶ Side effects of Adamax?
Limited human safety data. The engineering goal is to avoid the erythropoietic side effects of native EPO; Adamax-class peptides should not raise hematocrit at standard research doses.
▶ Is Adamax banned in sports?
EPO and its analogs are prohibited at all times under WADA Section S2. Adamax's specific status depends on the exact analog; buyers should verify with the current WADA Prohibited List. Detection methods exist for the EPO peptide class.
SIGNATURE MOVES
IRR activation without RBC stimulation.
Anti-inflammatory + neuroprotective in animal models.
SOURCED FROM PEPPU LABS
Reference compounds documented on this page are available as research-grade material at Peppu Studio · ≥99% purity · per-batch Certificate of Analysis. For laboratory research use only. No human dose is recommended by this wiki.
▶ LAST UPDATED · 2026-05-19